Related references
Note: Only part of the references are listed.Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase
Francois-Xavier Mahon et al.
ANNALS OF INTERNAL MEDICINE (2018)
Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment
Masaya Okada et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study
David M. Ross et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2018)
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
Susanne Saussele et al.
LANCET ONCOLOGY (2018)
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study
Delphine Rea et al.
BLOOD (2017)
Measurement of BCR-ABL1 transcripts on the International Scale in the United States: current status and best practices
Ranjana Arora et al.
LEUKEMIA & LYMPHOMA (2017)
Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study
Delphine Rea et al.
HAEMATOLOGICA (2017)
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia
Gabriel Etienne et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study
A. Hochhaus et al.
LEUKEMIA (2017)
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Andreas Hochhaus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study
Delphine Rea et al.
HAEMATOLOGICA (2017)
De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial
Richard E. Clark et al.
LANCET HAEMATOLOGY (2017)
Tyrosine kinase inhibitor (TKI) therapy discontinuation in patients with CML in chronic phase: A US clinical practice perspective.
Ellen K. Ritchie et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
A. Hochhaus et al.
ANNALS OF ONCOLOGY (2017)
Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management
Jorge E. Cortes et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
Pediatric chronic myeloid leukemia is a unique disease that requires a different approach
Nobuko Hijiya et al.
BLOOD (2016)
Moving treatment-free remission into mainstream clinical practice in CML
Timothy P. Hughes et al.
BLOOD (2016)
Adherence to Monitoring Tests in Patients With Chronic Myeloid Leukemia in Lebanon
Marcel Massoud et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2016)
Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study
Sung-Eun Lee et al.
HAEMATOLOGICA (2016)
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population
Hannah Bower et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The concept of treatment-free remission in chronic myeloid leukemia
S. Saussele et al.
LEUKEMIA (2016)
Rationale and protocol of CML study: cognitive and emotional impact of discontinuation of therapy in patients with chronic myeloid leukemia
Silvia Riva et al.
TUMORI JOURNAL (2016)
Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study
Sung-Eun Lee et al.
HAEMATOLOGICA (2016)
Rationale and protocol of CML study: cognitive and emotional impact of discontinuation of therapy in patients with chronic myeloid leukemia
Silvia Riva et al.
TUMORI JOURNAL (2016)
Unplanned discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia
Yutaka Tsutsumi et al.
MOLECULAR AND CLINICAL ONCOLOGY (2016)
The impact of dasatinib on pregnancy outcomes
Jorge E. Cortes et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Clinical features of pulmonary arterial hypertension in patients receiving dasatinib
Neil P. Shah et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia
N. C. P. Cross et al.
LEUKEMIA (2015)
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient- based survey on 1133 patients
Massimo Breccia et al.
LEUKEMIA RESEARCH (2015)
COST-EFFECTIVENESS OF NILOTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA ELIGIBLE TO START THE TREATMENT-FREE REMISSION PHASE IN ITALY
A. Aiello et al.
VALUE IN HEALTH (2015)
Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials
Koji Sasaki et al.
LANCET HAEMATOLOGY (2015)
Treatment-free remission after imatinib discontinuation is possible in paediatric patients with chronic myeloid leukaemia
Fiorina Giona et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)
Henrik Hjorth-Hansen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2015)
Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Discontinuation of Imatinib: A Tyrosine Kinase Inhibitor Withdrawal Syndrome?
Johan Richter et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV
Ruediger Hehlmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease
Philippe Rousselot et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
Stacie B. Dusetzina et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience
Ohad Benjamini et al.
LEUKEMIA & LYMPHOMA (2014)
Imatinib Cessation in Children and Adolescents With Chronic Myeloid Leukemia in Chronic Phase
Frederic Millot et al.
PEDIATRIC BLOOD & CANCER (2014)
Tyrosine Kinase Inhibitors and Pregnancy
Elisabetta Abruzzese et al.
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES (2014)
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani et al.
BLOOD (2013)
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
David M. Ross et al.
BLOOD (2013)
Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: A randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON)
Noortje Thielen et al.
EUROPEAN JOURNAL OF CANCER (2013)
Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular response
Laurence Legros et al.
BLOOD (2012)
Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response
Ho-Young Yhim et al.
LEUKEMIA RESEARCH (2012)
Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population
Fabio Efficace et al.
BLOOD (2011)
Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay
Hyun-Gyung Goh et al.
LEUKEMIA & LYMPHOMA (2011)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon et al.
LANCET ONCOLOGY (2010)
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Moshe Talpaz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Pregnancy among patients with chronic myeloid leukemia treated with imatinib
P Ault et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Complete cytogenetic and molecular responses to interferon-α-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis
HM Kantarjian et al.
CANCER (2003)
Share Paper
